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By Nancy M. Heddle and Morris A. Blajchman 
F 
OUR YEARS AGO an editorial in  Blood identified a 
number of  issues concerning policy decision-making 
about the clinical use of leukodepleted cellular blood prod- 
ucts to prevent HLA-alloimmunization and refractoriness to 
transfused  allogeneic platelets.’ In  that  editorial, Schiffer 
concluded that it was premature to recommend platelet leu- 
kodepletion  for  routine  use. The issues  identified  in  that 
editorial included the following: (1) The applicability of the 
available results to the general leukemic population, because 
most  studies had  been  done using highly selected patient 
populations. (2) The lack of available data on the effective- 
ness  of  leukodepletion to  prevent  HLA-alloimmunization 
and platelet refractoriness in individuals who were already 
alloimmunized, including those  who had  been  transfused 
previously andor females with a history of prior pregnan- 
cies. (3) The inconsistency in the degree of leukodepletion 
of  the cellular blood products used in the  various studies 
reported. (4)  The economic implications of  leukodepleting 
all cellular blood products when the potential clinical benefit 
might be available to only  a small percentage of  patients 
who  would  be  receiving such products. 
During the 4 years since that editorial, three more clinical 
trials reporting on the use of  leukodepleted cellular blood 
products have appeared.24  These include the article by Sint- 
nicolaas et a1  in  this issue of  Blood.4 In addition, several 
international forums and consensus conferences have been 
held to  try to deal with the indications for the clinical use 
of leukodepleted cellular blood produ~ts.~”  Are the answers 
to the unresolved issues, previously identified by  Schiffer, 
on which to make policy decisions about the use of leukode- 
pleted  cellular blood  products now  available? As  will be 
outlined below, even though much of the available data are 
tantalizing, the actual clinical benefit for the leukodepletion 
of cellular allogeneic blood products has not been established 
for most indications suggested for their use. 
Research methodologists and epidemiologists have pro- 
vided a very useful framework that can be applied to try to 
address the issues relating to the clinical use of leukodepleted 
cellular blood prod~cts.~,~  This approach involves the careful 
assessment of  the published data to determine: the validity 
of  the methodology used; the magnitude of  the treatment 
effect; and whether the results of a particular study are rele- 
vant  to  the care given to a specific patient. This methodologic 
framework for critical appraisal has been used  to  evaluate 
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five randomized controlled trials (RCTs), published between 
1983 and 1991,  which investigated the efficacy of leukode- 
pletion  to reduce the frequency of  HLA-alloimmunization 
and platelet refractoriness in patients who required cellular 
blood product transfusions.” 
Validity of  the  Methodology 
The critical appraisal of  the five RCTs published high- 
lighted several methodologic issues that might have biased 
the final results of  the  studies. These issues included the 
failure to blind patients and study personnel to the treatment 
allocation; a lack of similarity between patients in each treat- 
ment group, which usually resulted from exclusion of  pa- 
tients after  randomization; and  the  possibility of  patients 
receiving nonexperimental treatments that could affect the 
study  results.  However,  even  when  the  impact  of  these 
issues on the treatment effect were considered, there was 
still good evidence that the leukodepletion of the transfused 
cellular allogeneic blood products to a level below 5 X  IO6 
leukocytes per product could prevent HLA-alloimmuniza- 
tion. 
The Magnitude of  the  Treatment  Effect 
The magnitude of  the effect of  leukodepletion was ascer- 
tained by  performing a meta analysis on the data from the 
five studies. Using this approach, the common odds ratio 
for HLA-alloimmunization was estimated to be 0.27 (95% 
confidence interval [CI] 0.13 to 0.55) whereas that for plate- 
let refractoriness was  estimated at 0.28 (95%  C1 0.13 to 
0.54), suggesting that the frequencies of both HLA-alloim- 
munization and platelet refractoriness were lower in patients 
who received leukodepleted cellular blood  products com- 
pared  with  those who  did  not. 
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Relevance to Patient Care 
To determine whether study results are relevant to patient 
care, three questions must be considered: (1) Are the results 
of  the published studies generalizable? (2) Were clinically 
important outcomes considered? and (3) Are the benefits of 
leukodepletion cost-effective? These  three questions must 
be addressed satisfactorily before the routine leukodepletion 
of  all  cellular  allogeneic  blood  products  can  be  recom- 
mended. 
Are the  results generalizable  (ie, can they be  applied  to 
all  patients)?  In his 1991 editorial, Schiffer identified two 
issues that prevented generalizability of the data then avail- 
able.’ These included (a) the heterogeneity of the subjects 
used  in the reported studies, and (b) the absence of informa- 
tion  on  study  subjects who may  have been alloimmunized 
previously. Two of the three clinical studies published over 
the  past 4 years also involved heterogenous patient popula- 
tions, thus the first of these two issues remains unresolved. 
However, the  study by  Sintnicolaas et a1  in  this issue of 
Blood provides very  useful information on the effectiveness 
of  leukodepletion in the group of  patients with a high risk 
for prior alloimmunization; ie, females with a history of prior 
pregnancies4 
Using a randomized controlled double-blind design, the 
effect  of  leukodepletion  on  HLA-alloimmunization  and 
platelet refractoriness was investigated in 75 female patients 
with hematologic malignancies who had a prior history of 
one or more pregnancies. In contrast to most of  the other 
published studies, no statistically significant difference was 
seen in this cohort of  patients in the frequencies of  HLA- 
alloimmunization  or  refractoriness  to  allogeneic  platelet 
transfusions. The authors speculate that prior exposure to 
HLA antigens, during a previous pregnancy, resulted  in a 
boostering of  previously formed HLA alloantibodies, caus- 
ing  the  refractoriness. The authors raise the possibility that 
this  secondary  HLA-alloimmunization  could  have  been 
caused by  residual leukocytes, andor by  soluble antigens 
or microparticles present in the transfused allogeneic blood 
products, which escaped the leuko-filtration process. Indeed, 
there is experimental animal as well as human data to support 
the latter hypothesis.’’”3 However, it is important to note 
that the power of the study of Sintnicolaas et a1  to detect a 
statistically  significant difference  was  low  because  there 
were only 62 evaluable patients in this study. For this study 
to have shown a 50% reduction in the frequency of platelet 
refractoriness (ie, a decrease from 41%  to 20%), approxi- 
mately  90  subjects per treatment group would have been 
required. 
Were  all  clinically  important  outcomes  considered? 
HLA-alloimmunization and platelet transfusion refractori- 
ness have been  used, for a long time, as surrogate laboratory 
measurements for morbidity or mortality caused by bleeding 
in  thrombocytopenia patients.  Recently, the  clinical rele- 
vance of  these laboratory endpoints have been brought in 
question for several reasons.”  Alloimmunization is  defined 
by  the ability to detect HLA antibodies; thus, it is a labora- 
tory outcome measure. Refractoriness is used as the clinical 
outcome measure and is based on the posttransfusion platelet 
count. There are several potential problems with these surro- 
gate outcomes, even though there is evidence indicating that 
the likelihood for clinical bleeding correlates inversely with 
the peripheral blood platelet count.I4 
To our knowledge, there have  not  been  any formal studies 
that validate the correlation of bleeding with either platelet 
refractoriness to allogeneic platelet transfusions or the pres- 
ence of  HLA-alloantibodies in a patient’s serum. Refractori- 
ness  usually  involves the  enumeration of  posttransfusion 
platelet increments but  only  in  situations where other clinical 
factors known to adversely affect the posttransfusion platelet 
response are absent. The relevance of such an assessment is 
questionable because the majority of patients with  significant 
morbidity  or  mortality associated with bleeding are often 
septic, febrile, and/or are receiving antibiotic agents, such 
as amphotericin B.  Moreover, most reported studies censor 
patients once they  have been defined as being refractory; 
thus, clinical follow-up throughout a particular patient’s en- 
tire clinical course usually does not occur. Such an approach 
cannot be justified because some patients become refractory 
to  allogeneic  platelet  transfusions  early  in  their  illness 
whereas others, over time, move  in  and  out  of  the refractory 
state during the course of  their treatment.I5 
Further confusion results from variability in the definition 
of  the term ‘refractory’ used by different investigators. Sint- 
nicolaas et al  define refractoriness as “two consecutive plate- 
let transfusions with l-hour posttransfusion platelet recover- 
ies less than 20% in the absence of  clinical factors known 
to  adversely affect platelet recovery; or, a  single platelet 
transfusion with less than 20% recovery  in  the  presence of 
HLA antib~dy.”~  This definition differs from that used in 
other studies in which corrected count platelet increments 
of <7.5  X  109/L  or  <2.5  X 109/L  were used to define platelet 
refractorines~.’~.”  Moreover, in comparing each study’s as- 
sessment of refractoriness, poor responses were not required 
to be consecutive in one study17 and, in another, information 
was  not  provided  about  the  presence  of  clinical  factors 
known  to affect the posttransfusion platelet increment at the 
time of  assessment.’* For  all of  these reasons, the use  of 
refractoriness to platelet transfusions as a clinical outcome 
measure should be reassessed and perhaps a more clinically 
relevant outcome measure implemented. 
The rationale for  the clinical use  of  allogeneic platelet 
transfusions is to prevent or control bleeding. The use  of 
clinical bleeding as a primary outcome measurement has not 
been  widely  used. This is because mortality due to bleeding 
is  very  infrequent; thus, clinical studies using bleeding as an 
endpoint would require a large number of  study subjects to 
show  a statistically significant treatment effect. Moreover, 
bleeding is difficult to quantitate, although some investiga- 
tors have used a bleeding measurement scale to try to address 
this issue.”.”  For  all  of the reasons detailed above, there is 
general consensus that morbidity  and mortality caused by 
bleeding cannot be  used  as the clinical outcome measure to 
assess the effectiveness of allogeneic platelet transfusions. 
Is there an alternative that might be more clinically rele- 
vant  than  to  continue using HLA-alloimmunization and/or 
platelet transfusion refractoriness as surrogate outcome mea- 
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an index evaluating the percentage of days at risk of bleeding 
as a possible alternative outcome measure for bleeding.”  If 
allogeneic platelets are transfused and the patient has a good 
posttransfusion platelet count increment, then the patient is 
at  lower risk  for  bleeding. Although this index is  still a 
surrogate measure for bleeding, it would evaluate patients 
throughout their entire clinical course, even when other fac- 
tors known to affect the posttransfusion platelet response 
might be present. Thus, the effectiveness of leukocyte filtra- 
tion over time to improve the posttransfusion platelet re- 
sponse could be evaluated rather than the efficacy of only  a 
few platelet transfusion episodes. 
Are the beneJts of leukodepletion cost-effective?  The  ef- 
fectiveness of an intervention (measured in a realistic clinical 
setting) must be known to answer this question: Most would 
agree that potential harm caused by the use of leukodepleted 
allogeneic blood products is not an issue, because there are 
probably no side effects associated with their use compared 
with the use of  nonleukodepleted cellular allogeneic blood 
products.2’  However, the cost-benefit issue has not been ade- 
quately addressed. Schiffer has estimated that only 10% to 
15% of  individuals receiving leukodepleted blood products 
would  benefit  from  such an  intervention.’ To provide an 
estimate of potential benefit using the concept of  “number 
needed to treat”  we have estimated a relative risk reduction 
for platelet refractoriness of 70% and  a 4.1  % frequency for 
a clinically significant bleed.”  Based on these estimates, we 
have calculated that one would have to administer leukode- 
pleted blood products to 47 patients to prevent one clinically 
significant bleeding episode. It is  important to emphasize 
that this analysis is based on a relative risk reduction for 
platelet refractoriness and not risk reduction for bleeding. 
Because morbidity and mortality caused by  bleeding does 
not occur in all refractory patients, this “number needed to 
treat’ ’ is probably underestimated. 
CONCLUSIONS 
It appears that the necessary information on which to make 
a policy decision regarding the routine use of  leukodepletion 
for cellular blood products to prevent HLA-alloimmuniza- 
tion andor platelet refractoriness is still lacking. Moreover, 
it would be unreasonable to make such a policy decision only 
on the alloimmunization issue because there are a number of 
other potential clinical benefits to patients that might accrue 
if  leukodepleted  cellular  allogeneic  blood  products  were 
available for regular clinical use. These include the preven- 
tion of cytomegalovirus infection,” the prevention of nonhe- 
molytic febrile transfusion  reaction^:^ the prevention of the 
immune suppression in recipients which may affect the fre- 
quency of  postoperative infections and even tumor recur- 
rence,2’  and the potential prevention of  graft-versus-host dis- 
ease.”  Although  considerable  data  exist  relating  to  the 
efficacy of leukodepletion for some of these clinical indica- 
tions, cost-benefit analyses are lacking. The decision as to 
when to recommend the widespread use of leukodepletion 
of  cellular blood products is thus a rather difficult one and 
should be based on data from studies of all potential benefits 
for such a manoeuvre. 
Finally, the issue of  when to perform the leukodepletion 
of cellular allogeneic blood products must still be addressed. 
Technology is now readily available to enable the leukode- 
pletion of cellular blood products at the time of  collection 
(prestorage leukodepletion) rather than poststorage (ie, bed- 
side leukodepletion). Available data from studies in experi- 
mental  animals suggest that prestorage  leukodepletion of 
cellular blood products might be more effective at preventing 
alloimmunization and platelet refractoriness than poststorage 
leukodepletion.”.” Clinical data in humans are not  yet avail- 
able that validate this interesting observation. Moreover, data 
on  the extent of  leukodepletion for the  various proposed 
clinical indications have not yet been established. 
It is critical that individuals working within each of these 
research areas provide valid and clinically relevant data on 
which the decision to leukodeplete cellular allogeneic blood 
products can be made. Properly designed prospective clinical 
trials are still needed to address many of the issues outlined 
above, as well as to help define the optimal conditions for 
the preparation of leukodepleted cellular blood products for 
clinical use. Sound data are essential to enable sound policy 
decisions to be made about the clinical value of leukodeple- 
tion. When such data become available, the decision to rou- 
tinely  leukodeplete all  allogeneic cellular blood  products 
should be  made by  an  appropriate body  of  experts. This 
body should include methodologists, health care economists, 
policy decision analysts, as well as the investigators. 
REFERENCES 
1.  Schiffer C: Editorial: Prevention of alloimmunization against 
platelets. Blood 77: 1,  1991 
2.  Williamson LM, Wimperis JZ, Williamson P, Copplestone JA, 
Gooi HC, Morgenstern GR, Norfolk DR. for the Alloimmunization 
Group: Bedside filtration of  blood products in  the prevention of 
HLA alloimmunization-A  prospective randomized study. Blood 
83:3028, 1994 
3. Oksanen  K  Leukocyte-depleted blood  components prevent 
platelet refractoriness in patients with acute myeloid leukemia. Eur 
J Haematol 53:100, 1994 
4.  Sintnicolaas K,  van  Marwijk Kooij M, van Prooijen HC, van 
Dijk BA, van  Putten WLJ,  Claas  FHJ, Novotny VMJ,  Brand A: 
Leukocyte depletion of  random single donor platelet transfusions 
does not prevent secondary HLA-alloimmunization and refractori- 
ness: A randomized prospective study. Blood 85:824, 1995 
5. The Royal College of  Physicians and Surgeons of Edinburgh. 
Consensus Conference: Leukocyte Depletion of  Blood and Blood 
Components. Edinburgh, Scotland, 1993 
6. Seghatchian MJ: International Forum. An overview of labora- 
tory  and  clinical aspects of  leukocyte-depleted blood components. 
UK: Discussions on leukocyte depletion. Transfus Sci 15:49, 1994 
7.  Sekiguchi S: Clinical application of leukocyte depletion. Ro- 
ceedings of the 3rd Hokkaido Symposium on Transfusion Medicine. 
London, UK, Blackwell Scientific, 1993 
8. Guyatt GH, Sackett DL, Cook DJ,  for the  Evidence-Based 
Medicine Working Group: Users’ guides to the medical literature. 
ii.  How  to use an article about therapy or prevention. A.  Are the 
results of the study valid? JAMA  270:2598,  1993 
9.  Guyatt GH, Sackett DL, Cook DJ,  for the  Evidence-Based 
Medicine Working Group: Users’ guide to the medical literature. ii. 
How  to  use an article about therapy or prevention. B. What were 
the results and will they help me  in  caring for my patients? JAMA 
27159, 1994 
10.  Heddle NM: The efficacy of leukodepletion to improve plate- 606  HEDDLE AND  BLAJCHMAN 
let  transfusion  response:  A  critical  appraisal  of  clinical  studies. 
Transfus Med Rev 8: IS: 1994 
11.  Blajchman  MA,  Bardossy  L,  Carmen  RA,  Goldman  M,  Hed- 
dle  NM,  Singal  DP:  An  animal  model  of  allogeneic  donor  platelet 
refractoriness:  The  effect  of  the  time  of  leukodepletion.  Blood 
79:1371,  1992 
12.  Bordin JO, Bardossy L, Blajchman  MA:  Experimental  animal 
model  of  refractoriness to  donor  platelets:  The  effect  of  plasma 
removal  and  the  extent  of  white  cell  reduction  on  allogeneic  alloim- 
munization.  Transfusion  33:798,  1993 
13. Pellegrino  MA,  Indiveri  F,  Fagilolo  U, Antonello  A,  Ferrone 
S: Immunogenicity  of  serum  HLA  antigens  in allogeneic  combina- 
tions.  Transplantation  33:530,  1982 
14. Harker  LA,  Slichter SJ: The  bleeding  time  as  a  screening test 
for evaluation of platelet  function.  N  Engi J Med 287: 155, 1972 
15.  Lee EJ, Schiffer  CA:  Serial  measurement  of  lymphocytotoxic 
antibody  and  response  to non-matched  platelet  transfusions  in allo- 
immunized  patients.  Blood  70:  1727,  1987 
16.  Schiffer CA, Dutcher JP,  Aisner J,  Hogge  D,  Wiernik  PH, 
Reilly JP:  A  randomized trial of  leukocyte-depleted platelet transfu- 
sion to modify  alloimmunization in patients  with  leukemia.  Blood 
62:815,  1983 
17.  Oksanen K,  Kekomaki  R,  Ruutu  T,  Koskimies  S, Myllylla 
G: Prevention  of  alloimmunization  in  patients  with  acute  leukemia 
by  use  of  white  cell-reduced  blood  components-A  randomiled 
trial.  Transfusion  31 :.588,  1991 
18.  Andreu  G, Dewailly  J, Leberre C, Quarre  MC,  Bidet  ML. 
Tardive1 R,  Devers  L, Lam  Y, Soreau  E,  Boccaccio C, Piard  N. 
Bidet  JM,  Genetet  B, Fauchet  R:  Prevention  of HLA  immunization 
with  leukocyte-poor  packed  red cells  and  platelet  concentrate\  ob- 
tained by  filtration.  Blood  72:964,  1988 
19. Gmiir J, Burger  J,  Schanz  U, Fehr J, Schaffner A: Safety or 
stringent  prophylactic  platelet  transfusion  policy  for  patients  with 
acute  leukemia.  Lancet  338:1223,  1991 
20.  Lawrence  JB,  Yomtovian  R,  Hammons  T,  Masarik  S,  Lazarus 
HM: Lowering  the  prophylactic  platelet  transfusion  (ProPltTx)  trig- 
ger:  A  prospective  analysis.  Transfusion  34:53S,  1994 (abstr,  suppl) 
21.  Bordin  J, Heddle  NM,  Blajchman  MA:  Biologic  effects  of 
leukocytes  present  in  transfused  cellular  blood  products.  Blood 
84:  1703,  1994 
22.  Bowden  RA.  Cays  M,  Schoch C, Sayers  M,  Slichter  SJ, Welk 
K, Hoake  R,  McCullough  J, Weisdorf  D.  Miller  W: Comparison of 
filtered blood  (FB)  to  seronegative blood products  (SB)  for  preven- 
tion  of  cytomegalovirus  (CMV)  infection  after  marrow  transplant. 
Blood 82:204a, 1993 (abstr,  suppl  I ) 
23.  Heddle  NM, Klama L,  Singer J, Richards C,  Fedak  P,  Walker 
1,  Kelton  JG: The role of  the  plasma  from  platelet  concentrates in 
transfusion  reactions.  N Engl  J  Med 331525, 1994 